It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Late-life depression (LLD) is a heterogenous mood disorder influenced by genetic factors. Cortical physiological processes such as cortical inhibition, facilitation, and plasticity may be markers of illness that are more strongly associated with genetic factors than the clinical phenotype. Thus, exploring the relationship between genetic factors and these physiological processes may help to characterize the biological mechanisms underlying LLD and improve diagnosis and treatment selection. Transcranial magnetic stimulation (TMS) combined with electromyography was used to measure short interval intracortical inhibition (SICI), cortical silent period (CSP), intracortical facilitation (ICF), and paired associative stimulation (PAS) in 79 participants with LLD. We used exploratory genome-wide association and gene-based analyses to assess for genetic correlations of these TMS measures. MARK4 (which encodes microtubule affinity-regulating kinase 4) and PPP1R37 (which encodes protein phosphatase 1 regulatory subunit 37) showed genome-wide significant association with SICI. EGFLAM (which encodes EGF-like fibronectin type III and laminin G domain) showed genome-wide significant association with CSP. No genes met genome-wide significant association with ICF or PAS. We observed genetic influences on cortical inhibition in older adults with LLD. Replication with larger sample sizes, exploration of clinical phenotype subgroups, and functional analysis of relevant genotypes is warranted to better characterize genetic influences on cortical physiology in LLD. This work is needed to determine whether cortical inhibition may serve as a biomarker to improve diagnostic precision and guide treatment selection in LLD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Centre for Addiction and Mental Health, Temerty Centre for Therapeutic Brain Intervention, Toronto, Canada (GRID:grid.155956.b) (ISNI:0000 0000 8793 5925); Temerty Faculty of Medicine, University of Toronto, Department of Psychiatry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
2 Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada (GRID:grid.155956.b) (ISNI:0000 0000 8793 5925)
3 Centre for Addiction and Mental Health, Temerty Centre for Therapeutic Brain Intervention, Toronto, Canada (GRID:grid.155956.b) (ISNI:0000 0000 8793 5925); Temerty Faculty of Medicine, University of Toronto, Department of Psychiatry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada (GRID:grid.155956.b) (ISNI:0000 0000 8793 5925); University of Toronto, Toronto Dementia Research Alliance, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
4 Stanford University Medical Center, Department of Psychiatry and Behavioral Sciences, Stanford, USA (GRID:grid.240952.8) (ISNI:0000000087342732)
5 Temerty Faculty of Medicine, University of Toronto, Department of Psychiatry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada (GRID:grid.155956.b) (ISNI:0000 0000 8793 5925); University of Toronto, Toronto Dementia Research Alliance, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
6 University of Arizona College of Medicine, Department of Psychiatry, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
7 University of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
8 Washington University School of Medicine, Department of Psychiatry, St Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
9 University of California San Diego, Department of Psychiatry, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
10 Temerty Faculty of Medicine, University of Toronto, Department of Psychiatry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada (GRID:grid.155956.b) (ISNI:0000 0000 8793 5925)
11 Centre for Addiction and Mental Health, Temerty Centre for Therapeutic Brain Intervention, Toronto, Canada (GRID:grid.155956.b) (ISNI:0000 0000 8793 5925); Temerty Faculty of Medicine, University of Toronto, Department of Psychiatry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada (GRID:grid.155956.b) (ISNI:0000 0000 8793 5925)